Eric Pauwels Sells 3,202 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) insider Eric Pauwels sold 3,202 shares of the business’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $75.06, for a total transaction of $240,342.12. Following the sale, the insider directly owned 70,373 shares of the company’s stock, valued at $5,282,197.38. This represents a 4.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Eric Pauwels also recently made the following trade(s):

• On Wednesday, December 17th, Eric Pauwels sold 40,290 shares of PTC Therapeutics stock. The stock was sold at an average price of $75.43, for a total value of $3,039,074.70.

PTC Therapeutics Stock Up 5.3%

Shares of NASDAQ PTCT traded up $3.98 during midday trading on Friday, hitting $78.57. The stock had a trading volume of 2,735,148 shares, compared to its average volume of 1,223,774. The company has a market capitalization of $6.31 billion, a PE ratio of 9.18, a P/E/G ratio of 0.27 and a beta of 0.47. The stock has a 50 day simple moving average of $73.32 and a 200-day simple moving average of $59.78. PTC Therapeutics, Inc. has a 1 year low of $35.95 and a 1 year high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 EPS for the quarter, topping the consensus estimate of ($1.19) by $1.39. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The firm had revenue of $211.01 million during the quarter, compared to analysts’ expectations of $177.42 million. During the same period in the previous year, the business earned ($1.39) earnings per share. The firm’s revenue for the quarter was up 7.2% on a year-over-year basis. As a group, analysts expect that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Smartleaf Asset Management LLC grew its holdings in PTC Therapeutics by 101.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 236 shares in the last quarter. Optiver Holding B.V. lifted its stake in PTC Therapeutics by 96.5% during the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 249 shares during the last quarter. Comerica Bank boosted its holdings in PTC Therapeutics by 868.5% in the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 469 shares in the last quarter. Quantbot Technologies LP boosted its holdings in PTC Therapeutics by 545.5% in the first quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 551 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its stake in PTC Therapeutics by 84.2% in the first quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 320 shares during the last quarter.

Analysts Set New Price Targets

PTCT has been the subject of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $118.00 price objective on shares of PTC Therapeutics in a research note on Wednesday, September 3rd. Weiss Ratings restated a “hold (c)” rating on shares of PTC Therapeutics in a research report on Monday. TD Cowen lifted their price objective on PTC Therapeutics from $50.00 to $63.00 and gave the stock a “hold” rating in a research report on Wednesday, November 5th. Cowen reiterated a “hold” rating on shares of PTC Therapeutics in a research report on Wednesday, November 5th. Finally, The Goldman Sachs Group upped their target price on PTC Therapeutics from $44.00 to $50.00 and gave the company a “sell” rating in a report on Wednesday, November 5th. Nine equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $76.00.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.